Kennedy Institute of Ethics Journal 19 (1):pp. 1-22 (2009)
Direct reprogramming of human skin cells makes available a source of pluripotent stem cells without the perceived evil of embryo destruction, but the advent of such a powerful biotechnology entangles stem cell research in other forms of moral complicity. Induced pluripotent stem cell (iPSC) research had its origins in human embryonic stem cell research and the projected biomedical applications of iPS cells almost certainly will require more embryonic stem cell research. Policies that inhibit iPSC research in order to avoid moral complicity are themselves complicit in preventable harms to patients. Moral complicity may be unavoidable, but a Blue Ribbon Panel charged with assessing the need for additional embryonic stem cell lines may ease a transition from embryonic stem cell research to clinical applications of iPS cells.
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
Comments on “Moral Complicity in Induced Pluripotent Stem Cell Research”.Byrnes W. Malcolm & J. Furton Edward - 2009 - Kennedy Institute of Ethics Journal 19 (2):202-205.
Developments in Stem Cell Research and Therapeutic Cloning: Islamic Ethical Positions, a Review.Hossam E. Fadel - 2012 - Bioethics 26 (3):128-135.
International Society for Stem Cell Research (ISSCR) Guidelines for the Conduct of Human Embryonic Stem Cell Research (December 2006).Bernard Dickens - unknown
No Ethical Bypass of Moral Status in Stem Cell Research.Mark Brown - 2013 - Bioethics 27 (1):12-19.
Compromise and Moral Complicity in the Embryonic Stem Cell Debate.Katrien Devolder & John Harris - 2005 - In Nafsika Athanassoulis (ed.), Philosophical Reflections on Medical Ethics. Palgrave-Macmillan.
Stem Cell Research: An Ethical Evaluation of Policy Options.Nikolaus Knoepffler - 2004 - Kennedy Institute of Ethics Journal 14 (1):55-74.
Uncertain Translation, Uncertain Benefit and Uncertain Risk: Ethical Challenges Facing First-in-Human Trials of Induced Pluripotent Stem (Ips) Cells.Ronald K. F. Fung & Ian H. Kerridge - 2013 - Bioethics 27 (2):89-96.
The Ethics of Moral Compromise for Stem Cell Research Policy.Zubin Master & G. K. D. Crozier - 2012 - Health Care Analysis 20 (1):50-65.
Added to index2009-03-11
Total downloads217 ( #17,329 of 2,158,177 )
Recent downloads (6 months)1 ( #356,322 of 2,158,177 )
How can I increase my downloads?